NCT05367856 is a Phase 2 clinical trial of Chidamide combined with BEAM in T Cell Lymphoma, sponsored by Ruijin Hospital.

Who is sponsoring NCT05367856?

NCT05367856 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT05367856?

Interventions in NCT05367856: Chidamide combined with BEAM.

What condition does NCT05367856 study?

NCT05367856 studies T Cell Lymphoma.

Is NCT05367856 still recruiting?

NCT05367856 is currently status unknown. Last updated 29 September 2022.

Last reviewed 2022-09-29 · How we verify

NCT05367856

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma

Status unknown Phase 2 Last updated 29 September 2022

What this trial tests

Phase 2 trial testing Chidamide combined with BEAM in T Cell Lymphoma in 23 participants. Status unknown.

Timeline

28 May 2022

Primary endpoint
1 June 2024

1 June 2025

Quick facts

Lead sponsor	Ruijin Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	28 May 2022
Primary completion	1 June 2024
Estimated completion	1 June 2025
Sites	1 location across China

Drugs / interventions tested

Chidamide combined with BEAM — full drug profile →

Conditions studied

T Cell Lymphoma — all drugs for T Cell Lymphoma →

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 65, any sex, with T Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-center, single-arm clinical study will evaluate the efficacy and safety of Chidamide combined with BEAM Pretreatment Regimen in ASCT treatment of TCL patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A, Zhou H, Yang J, Li M, et al · · 2023 · cited 81× · PMID 36797244 · DOI 10.1038/s41392-023-01342-6
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914
Chidamide-BEAM Conditioning plus Autologous Stem Cell Transplantation for T-cell Lymphoma: A Single-Arm, Single-Center, Phase 2 Trial
Ji M, shen y, Chen S, Mu R, et al · · 2026 · DOI 10.21203/rs.3.rs-9258298/v1

Verify or expand the search:

Other recruiting trials for T Cell Lymphoma

Currently open trials in the same condition.

NCT06420076 — Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using · Phase 1, PHASE2 · recruiting
NCT05230680 — Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) · Phase 1, PHASE2 · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05367856 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 29 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05367856.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing